LIVER CIRRHOSIS: THE ROLE OF INNOVATIVE TECHNOLOGIES AND BIOMARKERS

Authors

  • A’zamqulova Durdona Bahriddin qizi
  • Shamsiyeva Ozoda Bahtiyorovna
  • Tojiboyeva Sevinch Jasurovna
  • Raxmatullayeva Maftuna Fayzulla qizi Student of Dentistry
  • Mirsavurova Nilufar Rakhimberdievna Scientific Supervisor Senior Lecturer, Department of Histology

Keywords:

Liver cirrhosis, renal dysfunction, Cystatin C, NGAL, terlipressin, urinary albumin, biomarkers, BDAT, dialysis, pharmacotherapy.

Abstract

Chronic hepatitis lead to liver cirrhosis.Liver cirrhosis remains one of the most challenging chronic liver diseases in modern hepatology, characterized by progressive hepatic dysfunction and the development of multiple systemic complications, including renal impairment. This article highlights the significance of advanced medical technologies and innovative diagnostic and therapeutic strategies in the comprehensive management of patients with liver cirrhosis. The integration of targeted pharmacotherapy, regenerative medicine concepts, and novel biomarkers has substantially improved early diagnosis, risk stratification, and treatment outcomes in cirrhotic patients. The study emphasizes the role of modern diagnostic tools and personalized therapeutic approaches in improving clinical outcomes, quality of life, and overall survival of individuals with liver cirrhosis. The implementation of cutting-edge technologies represents a promising direction for optimizing patient-centered care in hepatology.

Downloads

Published

2026-01-13

Issue

Vol. 48 (2026)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format
  2. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. NonCommercial — You may not use the material for commercial purposes .
  3. NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  4. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits

How to Cite

LIVER CIRRHOSIS: THE ROLE OF INNOVATIVE TECHNOLOGIES AND BIOMARKERS. (2026). British Journal of Global Ecology and Sustainable Development, 48, 1-5. https://journalzone.org/index.php/bjgesd/article/view/801